Edge Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Edge Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.27M	Buy	3,699 +414	+13%	+$129K	0.11%	143
2018 Q1	$1.13M	Buy	3,285 +116	+4%	+$40.3K	0.11%	152
2017 Q4	$1.19M	Buy	3,169 +250	+9%	+$101K	0.12%	144
2017 Q3	$1.3M	Sell	2,919 -682	-19%	-$325K	0.14%	130
2017 Q2	$1.77M	Buy	3,601 +412	+13%	+$180K	0.2%	115
2017 Q1	$1.24M	Buy	3,189 +652	+26%	+$242K	0.15%	133
2016 Q4	$931K	Buy	+2,537	New	+$965K	0.12%	152

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Edge Advisors's REGN Position: Q2 2018 in Review

Edge Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2018, buying an estimated $129K and bringing the position to 3,699 shares worth $1.27M. The position accounts for 0.11% of the portfolio, ranked #143.

Edge Advisors first reported a position in REGN in Q4 2016 and has held it in 7 quarters since. The position peaked at $1.77M in Q2 2017. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

Edge Advisors held 3,699 shares of Regeneron Pharmaceuticals worth $1.27M as of Q2 2018.
Edge Advisors bought 414 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $129K.
Regeneron Pharmaceuticals made up 0.11% of Edge Advisors's portfolio in Q2 2018, its #143 holding.
Edge Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 7 quarters since.
Edge Advisors's Regeneron Pharmaceuticals position peaked at $1.77M in Q2 2017.
624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.